ASCO Annual Meeting

Vorasidenib May ‘Change the Treatment Paradigm’ for Low-Grade Glioma

June 5th 2023, 2:00pm

Article

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.

Side Effects Manageable From Talzenna/Xtandi Treatment in Prostate Cancer Subset

June 5th 2023, 1:00pm

Article

Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.

Elranatamab Elicits Early, Deep Responses in Relapsed/Refractory Myeloma

June 4th 2023, 9:00pm

Article

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Verzenio Dose Reductions Don’t Worsen Breast Cancer Outcomes for Older Patients

June 4th 2023, 7:00pm

Video

It may be more beneficial to reduce the dose of Verzenio rather than stop the drug altogether, according to the monarchE trial findings.

Three-Drug Regimen Is Promising Across Kidney Cancer Subtypes

June 4th 2023, 5:00pm

Article

Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.

Acupuncture Reduced Bladder Cancer Pain, Urinary Symptoms

June 4th 2023, 3:00pm

Video

Acupuncture reduced pain “in a very significant way” and urinary symptoms for patients with non-muscle invasive bladder cancer who were undergoing BCG therapy.

Welireg Plus Lenvima Has ‘Promising Antitumor Activity’ in Kidney Cancer Subset

June 4th 2023, 1:00pm

Article

Nearly three-fourths of patients with clear cell renal cell carcinoma had a disease response lasting 12 months or longer after being treated with Welireg and Lenvima, study data showed.

Pre- and Post-Surgical Keytruda Boosts Outcomes in Early NSCLC

June 4th 2023, 1:03am

Article

Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer.

An App Improved Anxiety, Depression Symptoms in Patients With Cancer

June 3rd 2023, 10:13pm

Article

Participants in the RESTORE study, results of which were presented this weekend at ASCO, saw “significant improvements” in depression and anxiety symptoms after using the Attune app.

Imjudo-Imfinzi Regimen Improves Survival With Manageable Side Effects in Liver Cancer Subset

June 3rd 2023, 8:00pm

Article

Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.